Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Notre Dame Intermédica on Its R$2.4 Billion Initial Public Offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the initial public offering by Notre Dame…
Aeglea BioTherapeutics $36 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $36 million SEC-registered common stock…
Shire $2.4 billion sale of its Oncology business to Servier
Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has…
Cellectis S.A. Follow-On Offering
Davis Polk advised the representatives of the underwriters in connection with the $175 million public offering by Cellectis…
PTC Therapeutics, Inc. Common Stock Offering
Davis Polk advised the lead book-running managers and representatives of the underwriters in connection with the SEC…
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of …
Davis Polk Advises iKang Healthcare on Its Acquisition by Yunfeng Capital and Alibaba
Davis Polk is advising iKang Healthcare Group, Inc. in connection with its acquisition for $41.20 per common share or $20.60…
Accelerate Diagnostics, Inc. $150 Million Convertible Senior Notes Offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Accelerate…
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $1.5 Billion Refinancing
Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction…
Xencor, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $226.3 million public offering of common stock of…